A 5-DRUG REMISSION INDUCTION REGIMEN WITH INTENSIVE CONSOLIDATION FOR ADULTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA - CANCER AND LEUKEMIA GROUP-B STUDY-8811
A 5-DRUG REMISSION INDUCTION REGIMEN WITH INTENSIVE CONSOLIDATION FOR ADULTS WITH ACUTE LYMPHOBLASTIC-LEUKEMIA - CANCER AND LEUKEMIA GROUP-B STUDY-8811
复制标题
DOI：
10.1182/blood.v85.8.2025.bloodjournal8582025
复制
发表时间：
1995-04-15
期刊：
影响因子：
20.3
通讯作者：
SCHIFFER, CA
中科院分区：
文献类型：
--
作者：
LARSON, RA;DODGE, RK;SCHIFFER, CA
这项II期多中心临床试验的目的是评估一种新的用于未经治疗的急性淋巴细胞白血病（ALL）成人的强化化疗方案，并前瞻性地检查临床和生物学特征对结果的影响。197例合格和可评价的患者（16 - 80岁;中位数32岁）接受环磷酰胺、柔红霉素、长春新碱、泼尼松和L-门冬酰胺酶治疗; 167例患者（85%）达到完全缓解（CR），13例（7%）患有难治性疾病，17例（9%）在诱导期间死亡。在年轻患者中观察到更高的CR率（对于那些
The goal of this phase II multicenter clinical trial was to evaluate a new intensive chemotherapy program for adults with untreated acute lymphoblastic leukemia (ALL) and to examine prospectively the impact of clinical and biologic characteristics on the outcome. One hundred ninety-seven eligible and evaluable patients (16 to 80 years of age; median, 32 years of age) received cyclophosphamide, daunorubicin, vincristine, prednisone, and L-asparaginase; 167 patients (85%) achieved a complete remission (CR), 13 (7%) had refractory disease, and 17 (9%) died during induction. A higher CR rate was observed in younger patients (94% for those